Avita Therapeutics Inc

NASDAQ:RCEL  
22.96
+0.87 (+3.94%)
Earnings Announcements

Avita Therapeutics Reports First Quarter 2021 Financial Results

Published: 11/10/2020 21:40 GMT
Avita Therapeutics, Inc. (RCEL) - Avita Therapeutics Reports First Quarter 2021 Financial Results.
Q1 Loss per Share $0.48.
Q1 Revenue $5.1 Million Versus Refinitiv Ibes Estimate of $4.9 Million.
Q1 Earnings per Share Estimate $-0.34 -- Refinitiv Ibes Data (analyst estimates).
Will Not Provide Financial Guidance at This Time.
Revenue is expected to be $6.06 Million
Adjusted EPS is expected to be -$0.41

Next Quarter Revenue Guidance is expected to be $6.74 Million
Next Quarter EPS Guidance is expected to be -$0.44

More details on our Analysts Page.